Vir Biotechnology (NASDAQ:VIR) and collaboration partner Alnylam Pharmaceuticals (NASDAQ:ALNY) announce a
new COVID-19 candidate, VIR-2703, an inhalable RNAi therapeutic that
targets the SARS-CoV-2 genome for the potential treatment and/or
prevention of the respiratory illness.
VIR-2703 has predicted reactivity against more
that 99.9% of the 4,300+ SARS-CoV-2 genomes currently available in
public databases, including the SARS-CoV genome from the 2003 SARS
outbreak.
The companies intend to meet with the FDA to discuss an accelerated path to clinical trials.
https://seekingalpha.com/news/3568167-vir-and-alnylam-identify-inhalable-drug-candidate-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.